Benchling vs Ro: employee equity compared
Secondary market prices, valuation trajectory, equity structure, and liquidity outlook for employees choosing between Benchling and Ro.
Benchling
Life science R&D platform combining electronic lab notebook, molecular biology tools, and LIMS (lab information management) for biopharma, biotech, and agricultural science.
No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Healthcare tech with long sales cycles; ISO/NSO options; regulatory milestones drive value
Ro
Telehealth platform offering primary care, men's health, women's health, and weight management through 50-state provider network and fully integrated pharmacy.
No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Healthcare tech with long sales cycles; ISO/NSO options; regulatory milestones drive value
Key differences for employees
Equity structure
Benchling grants ISO/NSO with strike prices ranging from $18–$30 depending on your grant year. Ro grants ISO/NSO with strike prices from $16–$26.
Secondary market premium
The secondary market is pricing Benchling at a +3% premium over its last primary round ($6.1B → $6.3B). Ro trades at +4% over its last round ($5B → $5.2B). A higher secondary premium signals stronger investor demand and potentially better near-term liquidity for employees looking to sell.
Revenue and growth
Benchling runs at $0.1B ARR, growing +30% YoY (solid). Ro runs at $0.6B ARR, growing +25% YoY (solid). Revenue growth rate matters for equity because it drives the peer-multiple valuation — the method most correlated with exit multiples.
Liquidity timeline
Benchling: No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Ro: No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Calculate your specific grant
Enter your actual shares, equity type, and strike price. PrivatePulse calculates your personal equity value at both companies using 4 independent methods.